Noven is a fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

About Noven - Timeline

Noven – 1987 to Today

Noven's history began in 1987 in Miami, Florida with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the U.S. platform for Hisamitsu, the world's largest patch manufacturer, with fully-integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and mental health.

October 2019
Secuado® (asenapine) transdermal system FDA approval
July 2016
Brisdelle® (paroxetine) and Pexeva® (paroxetine) acquired by Sebela Pharmaceuticals
February 2015
New Minivelle® (estradiol transdermal system) 0.025 mg/day Dose Now Available by Prescription in U.S. Pharmacies
November 2013
Launch of Brisdelle®
June 2013
Brisdelle® approved by the FDA
January 2013
Noven Women's Health team launches Minivelle®
December 2012
Noven acquires Minivelle®, establishes Women's Health sales team
October 2012
Minivelle®, world's smallest estrogen patch, approved by FDA
Noven's Northeast operations consolidated in Empire State Building co-headquarters
Noven reacquires Daytrana® (methylphenidate transdermal system) from Shire
Hisamitsu Carlsbad facility integrated with Noven operations
Noven acquired by Hisamitsu Pharmaceuticals; public company status concludes
Noven acquires JDS Pharmaceuticals, expanding its portfolio and sales capabilities
Shire and Noven launch Daytrana®
Shire licenses Noven's Daytrana® patch for ADHD
Launch of Vivelle-Dot® (estradiol transdermal system), the world's smallest estrogen patch at the time
Launch of CombiPatch® (estradiol/norethindrone acetate transdermal system), the first combination (two-drug) patch
Formation of Novogyne joint venture in Women's Health
Launch of Vivelle® (estradiol transdermal system), the first adhesive matrix estrogen patch
Noven becomes a public company
Noven founded by Steven Sablotsky
Minivelle Package Japan USA Flags Daytrana PackageVivelle Dot Vivelle Conveyor Vivelle Dot Approval Noven's Building Noven Company

Fast Facts

Core Business:

Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:



Over 325

Chairman &
Chief Executive Officer:

Dr. Naruhito Higo

Media, General Business
& Other Inquiries:

Tel: 305-253-1916

Partnering and Other Business Development Opportunities

Tel: 551-233-2700

Physican Payment
Sunshine Act Inquiries:

Employment Inquiries:

Rory Kelly
Associate Director – Recruiting
Careers Page

Community Support:

Corporate Social Responsibility

Affiliated Companies:

Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.

Noven's commercialized products are marketed and sold through Noven Therapeutics, LLC.

Grove Pharmaceuticals is the generic division of Noven Therapeutics, LLC.